miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2

Chronic myelogenous leukemia (CML), characterized by the presence of Philadelphia (Ph+) chromosome is a haematopoietic stem cell malignancy. Translocation of chromosome 9 and chromosome 22 leads to formation of BCR-ABL1 fusion gene, whose gene product drives and maintains pathogenesis of CML [1,2]. Tyrosine kinase inhibitors (TKIs) treatment have improved outcome of CML patients dramatically since its first application more than a decade ago [3]. Although receiving more potent second generation TKIs, such as dasatinib and nilotinib, some patients still experienced resistance and relapse [4,5].

Source: Experimental Hematology - September 5, 2018 Category: Hematology Authors: Bin Pan, Jing Yang, Xiangmin Wang, Kailin Xu, Takayuki Ikezoe Source Type: research